Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
KNTC1 knockdown suppresses cell proliferation of colon cancer.
Zhengxiang Z, Yunxiang T, Zhiping L, Zhimin Y. Zhengxiang Z, et al. Among authors: zhimin y. 3 Biotech. 2021 Jun;11(6):262. doi: 10.1007/s13205-021-02800-0. Epub 2021 May 11. 3 Biotech. 2021. PMID: 33996374 Free PMC article.
Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma.
Wang F, Chuner J, Lei W, Fengqin Y, Zhimin Y, Quanquan S, Tongxin L, Zhenfu F, Yangming J. Wang F, et al. Among authors: zhimin y. Medicine (Baltimore). 2020 Sep 25;99(39):e22283. doi: 10.1097/MD.0000000000022283. Medicine (Baltimore). 2020. PMID: 32991429 Free PMC article. Clinical Trial.
Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area.
Fangzheng W, Chuner J, Haiyan Q, Quanquan S, Zhimin Y, Tongxin L, Jiping L, Peng W, Kaiyuan S, Zhenfu F, Yangming J. Fangzheng W, et al. Among authors: zhimin y. Medicine (Baltimore). 2019 Dec;98(51):e18484. doi: 10.1097/MD.0000000000018484. Medicine (Baltimore). 2019. PMID: 31861031 Free PMC article.
Challenges in anticancer drug R&D in China.
Zhao S, Lv C, Gong J, Wenfeng F, Hu X, Ba Y, Xiaoyuan C, Zhimin Y, Shen L, Zhang L; Chinese Phase 1 Oncology trial Consortium. Zhao S, et al. Among authors: zhimin y. Lancet Oncol. 2019 Feb;20(2):183-186. doi: 10.1016/S1470-2045(18)30865-9. Lancet Oncol. 2019. PMID: 30723039 No abstract available.
Optimization of the margin expanded from the clinical to the planned target volume during intensity-modulated radiotherapy for nasopharyngeal carcinoma.
Fangzheng W, Quanquan S, Chuner J, Zhimin Y, Shuangyan Y, Huanhuan Y, Jianfang S, Sakamoto M, Weifeng Q, Zhenfu F, Yangming J, Yuezhen W. Fangzheng W, et al. Among authors: zhimin y. Oncotarget. 2017 Nov 20;8(66):110201-110208. doi: 10.18632/oncotarget.22518. eCollection 2017 Dec 15. Oncotarget. 2017. PMID: 29299141 Free PMC article.
14 results